How Does Palforzia Work? Mechanism of Action Explained in Plain English

When your child is diagnosed with a peanut allergy, their immune system has made a fundamental mistake: it has classified a harmless protein found in peanuts as a dangerous invader. Every time peanut protein is encountered, the immune system launches an aggressive — and sometimes life-threatening — defense response. Palforzia works by patiently correcting that mistake, one tiny dose at a time. Here is what that process looks like at the biological level, explained in plain English.

First, What Goes Wrong in Peanut Allergy?

In people with peanut allergy, the immune system has produced a large number of antibodies called Immunoglobulin E (IgE) that are specifically tuned to react to peanut proteins — primarily Ara h 1, Ara h 2, and Ara h 6. These IgE antibodies coat immune cells called mast cells and basophils, which are distributed throughout body tissues and the bloodstream.

When peanut protein enters the body and contacts these IgE-coated cells, it acts like a key fitting into a lock: the peanut protein (antigen) cross-links the IgE antibodies on the mast cell surface, causing the cell to immediately release a flood of inflammatory chemicals — including histamine, prostaglandins, and leukotrienes. This chemical flood is what produces the symptoms of an allergic reaction: hives, swelling, vomiting, throat tightness, and in severe cases, anaphylaxis.

How Palforzia Works: The Desensitization Process

Palforzia uses the principle of oral immunotherapy (OIT): deliberately exposing the immune system to the allergen — peanut protein — in controlled, gradually increasing amounts over time. This repeated, low-dose exposure retrains the immune system in several ways:

Mast cell and basophil desensitization: Chronic low-dose exposure causes mast cells and basophils to become less reactive to peanut protein over time. They still have IgE on their surface, but the trigger threshold is raised — meaning more peanut protein is needed to set them off.

Regulatory T-cell induction: Repeated allergen exposure promotes the growth of regulatory T-cells (Tregs), which act as a brake on the allergic immune response. Tregs help suppress the over-reactive immune signaling that drives allergy.

IgG4 antibody increase: OIT typically causes an increase in IgG4 antibodies specific to peanut proteins. IgG4 acts as a blocking antibody — it competes with IgE to bind peanut proteins before they can trigger mast cells, effectively intercepting the allergen before it can cause a reaction.

IgE reduction over time: While peanut-specific IgE levels may initially increase (which is why reactions are most common early in treatment), sustained OIT is associated with eventual reductions in IgE levels and peanut sensitivity over time.

What Exactly Is in Palforzia?

Palforzia is manufactured from defatted, roasted peanut flour and packaged in precisely measured capsules and sachets. Each dose form contains a specific, standardized quantity of peanut protein — including specific amounts of the three most allergenic peanut proteins, Ara h 1, Ara h 2, and Ara h 6, verified by immunoassay. This standardization is what distinguishes Palforzia from non-pharmaceutical peanut flour: every dose is precisely calibrated, eliminating the dose variability that exists when using grocery-store peanuts.

Why Does Palforzia Start at Such Low Doses?

The treatment starts at just 0.5 mg of peanut protein — an almost imperceptibly tiny amount. For context, a single peanut contains approximately 250-300 mg of peanut protein. Starting at 0.5 mg means the Initial Dose Escalation begins with roughly 1/500th the protein in one peanut. This extremely low starting point is deliberate: it allows the body to encounter the allergen without triggering a significant reaction, establishing the foundation for tolerance before the doses begin increasing.

The 3 mg dose — the starting point of the Up-Dosing phase — represents a meaningful milestone: the patient has already demonstrated they can tolerate this level during Initial Dose Escalation, and now their body will adjust to this as the daily home dose before advancing further.

39,049+ patients found their medications in stock

39K+

Find Palforzia 3 mg In Stock Today →

Does Palforzia Cure Peanut Allergy?

Palforzia induces desensitization — a state where the immune system can tolerate higher amounts of peanut protein than before — but it is not the same as a cure (sustained unresponsiveness). Desensitization requires ongoing daily dosing to maintain. If a patient stops taking Palforzia, their tolerance can diminish over time and sensitivity to peanut can return. This is why the Maintenance phase is described as long-term and ongoing.

How Does Palforzia Compare to Xolair (Omalizumab)?

Omalizumab (Xolair), the other FDA-approved therapy for food allergy, works completely differently. While Palforzia directly introduces the allergen to retrain the immune system, Xolair targets the IgE molecule itself — blocking the IgE antibody before it can dock on mast cells. Xolair doesn't retrain the immune system; it intercepts the allergic pathway at a molecular level. This means Xolair can protect against multiple food allergens simultaneously (not just peanut), but its protection depends entirely on continuous administration.

Skip the calls, skip the stress.

Find Palforzia 3 mg In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

The Palforzia Journey in 2026

Despite the scientific validation of its mechanism and proven clinical efficacy, Palforzia is being discontinued as of July 31, 2026 for commercial reasons. The complex REMS program requirements limited how many providers could offer it and how many patients could access it. Its scientific legacy — proving that food oral immunotherapy works — will outlast its commercial existence. For more on the current availability situation, read our guide on why Palforzia is so hard to find in 2026.